Article
Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation.
Clinical epigenetics - 16 Jan 2024
Godfrey Laura K, Forster Jan, Liffers Sven-Thorsten, Schröder Christopher, Köster Johannes, Henschel Leonie, Ludwig Kerstin U, Lähnemann David, Trajkovic-Arsic Marija, Behrens Diana, Scarpa Aldo, Lawlor Rita T, Witzke Kathrin E, Sitek Barbara, Johnsen Steven A, Rahmann Sven, Horsthemke Bernhard, Zeschnigk Michael, Siveke Jens T
Abstract excerpt
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor prognosis. It is marked by extraordinary resistance to conventional therapies including chemotherapy and radiation, as well as to essentially all targeted therapies evaluated so far. More than 90% of PDAC cases harbor an activating KRAS mutation. As the most common KRAS variants in PDAC remain undruggable so far, it seemed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.